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An unappreciated role for RNA surveillance For several of the PTC+ isoforms we identified, existing experimental evidence can be reinterpreted and is consistent with the action of  NMD to degrade the transcripts. Several genes with mRNA isoforms that we identified as PTC+ - calpain-10, the CDC-like kinases (CLKs)  and LARD - show how previous experimental results may be understood in light of NMD.
Abstract
Background:  Nonsense-mediated mRNA decay (NMD) is a eukaryotic mRNA surveillance
mechanism that detects and degrades mRNAs with premature termination codons (PTC+ mRNAs).
In mammals, a termination codon is recognized as premature if it lies more than about 50
nucleotides upstream of the final intron position. More than a third of reliably inferred alternative
splicing events in humans have been shown to result in PTC+ mRNA isoforms. As the mechanistic
details of NMD have only recently been elucidated, we hypothesized that many PTC+ isoforms may
have been cloned, characterized and deposited in the public databases, even though they would be
targeted for degradation in vivo.
Results: We analyzed the human alternative protein isoforms described in the SWISS-PROT
database and found that 144 (5.8% of 2,483) isoform sequences amenable to analysis, from 107
(7.9% of 1,363) SWISS-PROT entries, derive from PTC+ mRNA.
Conclusions: For several of the PTC+ isoforms we identified, existing experimental evidence can
be reinterpreted and is consistent with the action of NMD to degrade the transcripts. Several genes
with mRNA isoforms that we identified as PTC+ - calpain-10, the CDC-like kinases (CLKs) and
LARD - show how previous experimental results may be understood in light of NMD.
Background
Alternative pre-mRNA splicing endows genes with the poten-
tial to produce a menagerie of protein products. After pre-
mRNA is transcribed, a complex system of regulation deter-
mines which one of several possible versions of mature
mRNA will be produced (reviewed in [1]). Alternative splicing
is particularly important in human gene expression, as it
affects half or more of human genes [2,3]. The diversity-gen-
erating capacity of alternative splicing can be staggering:
one notable example, the dscam gene of Drosophila
melanogaster, is hypothetically capable of producing 38,016
unique alternative isoforms [4]. However, functional roles for
most alternative isoforms remain undiscovered.
It has been known for more than a decade that nonsense and
frameshift mutations that induce premature termination
codons can destabilize mRNA transcripts in vivo [5,6]. First
investigated in yeast and humans, NMD was subsequently
observed in a wide range of eukaryotes and is now thought to
occur in all eukaryotes [7]. How cells manage to distinguish a
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premature termination codon from a normal termination
codon has been the subject of intense investigation. Impor-
tant details have emerged that establish the following mecha-
nistic framework model for NMD in mammals (Figure 1).
During pre-mRNA processing, the spliceosome removes
intron sequences. As this occurs, a set of proteins called the
exon-junction complex is deposited 20-24 nucleotides
upstream of the sites of intron removal [8-11]. The compo-
nents of this complex serve the dual roles of facilitating export
of the mature mRNA to the cytoplasm and remembering the
gene structure [12]. According to the current model, as a
ribosome traverses the mRNA in its first pioneering round of
translation, it displaces all exon-junction complexes in its
path [13-16]. For normal mRNAs, whose termination codons
are on or near the final exon, the ribosome will have displaced
all exon-junction complexes. By contrast, if any exon-junc-
tion complexes remain when the ribosome reaches the stop
codon, a series of interactions ensues that leads to the decap-
ping and degradation of the mRNA. This model explains the
basis of the '50 nucleotide rule' for mammalian NMD: if a ter-
mination codon is more than about 50 nucleotides upstream
of the final exon, it is a PTC and the mRNA that harbors it will
be degraded [17]. The mechanisms for NMD differ among
yeast [18], flies [19], and mammals - and may be different still
in other eukaryotes.
Degradation of PTC+ mRNAs is generally thought to occur as
a quality-surveillance system -preempting translation of
potentially dominant-negative, carboxy-terminal truncated
proteins [20]. PTC+ transcripts are aberrantly produced in
several ways. The somatic recombination that underlies
immune-system diversity frequently generates recombined
genes whose transcripts contain a PTC [21]. Inefficient or
faulty splicing will often generate a frameshift in the resulting
mRNA, inducing a PTC to come into frame. Also, the high
processivity of RNA polymerase yields a relatively high error
rate, 1 in 10,000 bases [22,23], commonly introducing pre-
mature stops. DNA mutations are a source of potentially her-
itable PTCs. It is estimated that 30% of inherited disorders in
humans are caused by a PTC [24]. The numerous diseases
whose pathogenesis has been linked to NMD-inducing PTC
mutations include aniridia due to the PAX6 gene [25], Duch-
enne muscular dystrophy due to the dystrophin gene [26],
and Marfan syndrome due to the FBN1 gene [27].
In addition to its quality-control role in degrading aberrantly
produced PTC+  mRNAs, NMD has also been shown
Recognition of premature termination codons in humans is splicing dependent Figure 1
Recognition of premature termination codons in humans is splicing dependent. (a) During pre-mRNA processing, introns are removed and a set of 
proteins called the exon-junction complex is deposited. According to the current model for mammalian NMD, these complexes serve to facilitate 
transport from the nucleus and to remember the gene structure. During the first, pioneering, round of translation, the ribosome will displace all exon-
junction complexes in its path until it reaches a stop codon. If the termination codon is on or near the final exon, as is the case for most genes, the 
ribosome will have displaced all exon-junction complexes. The mRNA will then undergo multiple rounds of translation. (b) If the termination codon is 
sufficiently far upstream of the final intron position, exon-junction complexes will remain. Interactions ensue that result in the degradation of the mRNA by 
NMD.
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the exon-junction complex
More than
50 nucleotides
Gm AAAAA
NMD degradation Multiple rounds of normal translation
(a) Stop codon is on last exon (b) Stop codon is prematurehttp://genomebiology.com/2004/5/2/R8 Genome Biology 2004,     Volume 5, Issue 2, Article R8       Hillman et al. R8.3
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experimentally to act on a handful of wild-type PTC+ mRNAs
[28-35]. In Caenorhabditis elegans, for example, expression
of the ribosomal proteins L3, L7a, L10a and L12 and the SR
proteins SRp20 and SRp30b are regulated posttranscription-
ally via the coupling of alternative splicing and NMD [31,32].
In each case, productive isoforms were shown to be produced
in vivo, as well as unproductive isoforms with a PTC. Regu-
lated splicing to generate the unproductive isoforms is used
as a means of downregulating protein expression, as these
mRNA isoforms are degraded by NMD rather than translated
to make protein. This system, which we have termed regu-
lated unproductive splicing and translation (RUST), is also
used in humans [28-30]. For example, the SR protein SC35
has been shown to autoregulate its own expression using
RUST [29]. When levels of SC35 protein are elevated, SC35
binds its own pre-mRNA, inducing the production of PTC+
SC35 mRNA. The PTC+ SC35 mRNA is destabilized by NMD,
resulting in lower levels of SC35 protein. A similar autoregu-
latory RUST system was also recently discovered to control
production of polypyrimidine tract binding protein (PTB)
[35].
In a previous study, we found that 35% of human mRNA
alternative isoforms reliably inferred from expressed
sequence tags (ESTs) are PTC+, rendering them apparent tar-
gets of NMD (see [36] and a conference report at [37]. There-
fore, many wild-type alternative mRNA isoforms may not be
translated into functional protein, but instead are targeted for
degradation by NMD. The v a s t  m a j o r i t y  o f  P T C + isoforms
identified in that study represent previously unrecognized
potential targets of NMD. However, EST databases contain
expressed sequence for many isoforms that are otherwise
uncharacterized. Therefore, it was not obvious how many of
the isoforms identified in that study as PTC+ were function-
ally relevant or even previously known. It was also not obvi-
ous to what extent those PTC+ isoforms represented instances
of RUST regulation or simply errors or deregulation in pre-
mRNA processing. Regardless, it is clear that NMD has a vital
role in regulating mammalian gene expression, as inhibition
of NMD is embryonic lethal for mouse [38].
To understand the biological significance of PTC+ isoforms
and the prevalence of NMD on wild-type transcripts, it is nec-
essary to expand beyond existing isolated RUST examples,
while retaining a focus on functionally characterized genes.
For this reason, we analyzed the human alternative isoforms
described in the SWISS-PROT database. Common routes for
gene isoform sequences to be determined and entered into
databases include the cloning of intronless mini-genes and
the sequencing of unexpected PCR bands. By either method,
gene structure cannot be directly observed, and therefore
PTCs may be overlooked. Further computational and experi-
mental analyses will also often be oblivious to these features.
Because the cloning and characterization of many isoforms
predates our current understanding of NMD action, we
hypothesized that unrecognized potential targets of NMD
may be present even in curated databases like SWISS-PROT.
We found that many of these alternative protein isoforms
derive from PTC+ mRNAs. This is particularly surprising as
SWISS-PROT is a heavily curated database of expressed pro-
tein sequences. According to the current NMD model, these
PTC+ mRNAs should be degraded, and therefore the protein
isoforms should not be expressed at high abundance. To
resolve this apparent conflict, we examined existing experi-
mental evidence and found that, in several cases, results
described in the scientific literature are readily explained by
NMD action.
Results and discussion
SWISS-PROT protein isoforms from PTC+ mRNAs
We examined the human alternative isoforms described in
the SWISS-PROT database [39] to determine if any derive
from PTC+ mRNA (see Materials and methods). For each
alternative human protein isoform sequence in SWISS-
PROT, we attempted to identify a corresponding cDNA/
mRNA sequence in GenBank [40] or RefSeq [41]. As shown in
Figure 2, 2,742 isoform sequences from 1,463 SWISS-PROT
entries could be reliably mapped to a cDNA/mRNA sequence.
Next, we aligned each cDNA/mRNA sequence to the corre-
sponding region of genome sequence using the SPIDEY pro-
gram [42]. The SPIDEY output was analyzed to identify the
position of introns in each gene. To determine which cDNA/
mRNA sequences have PTCs according to the 50-nucleotide
rule for NMD, the position of the termination codon as
reported in each GenBank or RefSeq file was compared to the
position of the introns. Of 2,483 alternative isoforms from
1,363 SWISS-PROT entries that passed quality filters, 144
isoforms (5.8% of 2,483) from 107 entries (7.9% of 1,363)
were found to have PTCs, making them candidate targets of
NMD. We also found that SWISS-PROT entries that contain
multiple alternative isoforms amenable to our analysis were
more likely to contain at least one PTC+ isoform (see Figure
3). The complete list of PTC+ alternative isoforms we identi-
fied in this analysis, along with their SWISS-PROT accession
numbers and cDNA/mRNA identifiers, are shown in Table 1.
The SPIDEY alignments for each of the isoforms we identified
as PTC+ are provided as Additional data file 1.
Next we examined existing reports for experimental evidence
that would refute or support action of NMD on these PTC+
isoforms. We found that published descriptions of these PTC+
isoforms sometimes do describe the isoforms as containing
premature termination codons. However, these articles
almost universally lack any mention of NMD, even as they
often describe data that is suggestive of NMD action. Among
the many well-characterized proteins found in our study to
have at least one PTC+ splice variant, three examples demon-
strate how previously published experimental results may be
interpreted in the light of NMD degradation of alternative
mRNA isoforms.R8.4 Genome Biology 2004,     Volume 5, Issue 2, Article R8       Hillman et al. http://genomebiology.com/2004/5/2/R8
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Figure 2 (see legend on next page)
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Calpain-10
Calpain-10 is an ubiquitously expressed protease that is alter-
natively spliced to produce eight mRNA isoforms [43], found
in SWISS-PROT as Q9HC93. The gene for calpain-10 has
been intensively studied because a polymorphism in its third
intron, UCSNP-43, has been linked to type II diabetes in sev-
eral populations. Because this polymorphism lies in intronic
sequence it does not directly affect the coding potential of any
isoform of calpain-10. It was shown that homozygosity of
UCSNP-43 leads to reduced levels of total calpain-10
transcript and is coincident with insulin resistance in skeletal
muscle [44]. Previous investigations into how this polymor-
phism affects transcript abundance have centered on tran-
scriptional regulation [43,45]. In an expression study,
Horikawa et al. found four of the eight isoforms to be "less
abundant". In our SWISS-PROT survey we found these same
four mRNA isoforms to be PTC+, suggesting that NMD may
be responsible for this experimental observation (Figure 4).
This introduces the possibility that UCSNP-43 may affect the
regulation of calpain-10 alternative splicing, favoring produc-
tion of one or more of the PTC+ isoforms.
CDC-like kinases CLK1, CLK2 and CLK3
CLK1, CLK2 and CLK3 - three members of the CDC-like
kinase family (also known as LAMMER kinases and STY
kinases; SWISS-PROT entries P49759, P49760, P49761) -
were found to have at least one PTC+ splice variant. CLKs are
thought to be high-level regulators of alternative splicing, as
CLK1 has been shown to activate a set of SR proteins by phos-
phorylating them [46-48]. The pattern of alternative splicing
of each CLK paralog was found to be the same: a full-length
isoform and an isoform that skips exon 4 [49]. We found that
in each case, skipping exon 4 induces a frameshift that creates
a PTC (Figure 5a). The conceptual translations of these PTC+
isoforms, described as 'truncated,' lack most of the coding
region, including the kinase domain.
Having observed conservation amongst the human paralogs,
we examined the gene structures of the mouse orthologs of
each CLK (Figure 5b) to determine if the splicing pattern was
shared across species. We identified mouse orthologs through
existing RefSeq database annotation. EST evidence of alter-
native splicing showed that all three mouse CLK orthologs
showed the same pattern of alternative splicing, skipping
exon 4 to induce a PTC, as seen in the human CLKs. The sig-
nificance of this evolutionary conservation is underscored by
the recent finding that low-abundance alternative exons are
'mostly not conserved' between human and mouse [50]. For
the CLK genes, the alternative exons and the introns flanking
them are among the most similar regions of these genes (Fig-
ure 5b).
We next searched for evidence of more distant conservation
of CLK alternative splicing. We identified the single CLK
homolog in the sea squirt by using a hidden Markov model of
CLKs to search the Ciona intestinalis genome (see Materials
and methods). EST evidence clearly indicated that the same
alternative splicing pattern seen in human and mouse is also
conserved in C. intestinalis. We were not able to observe a set
of similar splicing patterns in D. melanogaster (data not
shown).
Menegay and co-workers "tested whether expression of CLK1
splice products was subject to regulation by cellular stressors"
[48]. They found that "UV exposure or high salt conditions
had no effect on the ratio of full-length to truncated splice
forms of CLK1. Cycloheximide, however, had a large effect,
changing the ratio dramatically in favor of the truncated
kinase-less form of mRNA" (see Figure 6). Cycloheximide, a
chemical inhibitor of translation, is known to inhibit NMD
[51], because NMD depends on translation. Indeed, cyclohex-
imide is now a commonly used reagent for NMD-inhibition
experiments (see, for example [28,52,53]). Combined with
our finding that the 'truncated' mRNA isoform possesses a
PTC, the results of Menegay et al. can be readily explained:
the increased abundance of the truncated PTC+ isoform fol-
lowing cycloheximide treatment is likely to be the result of
inhibiting NMD, which normally degrades it.
CLK1 has been shown to indirectly affect its own splicing [46]:
the presence of high levels of CLK1 protein favors generation
of the truncated PTC+ splice variant. However, instead of cod-
ing for an inactive, truncated protein isoform, we propose
that this PTC+ mRNA isoform may be simply degraded by
NMD. Autoregulation of this type would be analogous with
that seen for the splicing factors SC35 [29] and PTB [35]. Both
Many human alternative isoforms in SWISS-PROT derive from PTC+ mRNAs Figure 2 (see previous page)
Many human alternative isoforms in SWISS-PROT derive from PTC+ mRNAs. (a) We analyzed each of the human SWISS-PROT entries containing a 
VARSPLIC line in its feature table, using this information to assemble protein isoform sequences. Ambiguous VARSPLIC entries led us to discard five 
entries from our analysis at this point. (b) We next identified cDNA/mRNA sequences corresponding to each protein isoform assembled from SWISS-
PROT. BLAST was used to align each protein isoform sequence to translated cDNA/mRNA sequences in GenBank and Refseq, filtering to ensure only high 
confidence matches. To obtain the coding sequence of each mRNA/cDNA sequence, we used LocusLink to map each to the correct human genomic 
contig sequence from the NCBI human genome build 30. We referred to the CDS feature of each GenBank or RefSeq cDNA/mRNA record to identify 
stop codon locations. (c) We used the SPIDEY mRNA-to-genomic DNA alignment program to determine the gene structure of each mRNA/cDNA 
isoform sequence. After generating these gene structures, we could determine the PTC+ status on the basis of stop codon location relative to exon-exon 
junctions. If the termination codon was found to be more than 50 nucleotides upstream of the final intron, the transcript was deemed PTC+ and designated 
a candidate target of NMD according to the model of mammalian PTC recognition. (d) Each putative PTC+ isoform was manually inspected for errors in 
gene structure prediction. These errors include false exon predictions due to poly(A) tails and cDNA/mRNA sequence not seen in the corresponding 
genomic sequence.R8.6 Genome Biology 2004,     Volume 5, Issue 2, Article R8       Hillman et al. http://genomebiology.com/2004/5/2/R8
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SC35 and PTB proteins promote the alternative splicing of
PTC+ isoforms of their own mRNAs, which are then degraded
by NMD.
LARD/TNFRSF12/DR3/Apo3
Death-domain-containing receptors such as LARD (also
known as TNFRSF12, DR3 and Apo3; SWISS-PROT entry
Q99831) are known to regulate the balance between lym-
phocyte proliferation and apoptosis [54]. The term death
domain refers to a conserved intracellular region present in
receptors such as Fas and tumor necrosis factor receptor 1
(TNFR-1) that is capable of inducing apoptosis when the
receptor has bound its ligand (in these cases, Fas ligand and
tumor necrosis factor α (TNFα) respectively). The regulation
of functional death receptor expression is important in main-
taining the balance between lymphocyte proliferation and
apoptosis in vivo.
LARD is alternatively spliced to produce 12 isoforms [55].
There is one full-length isoform that encodes a death domain
and its expression is pro-apoptotic. Many of the 11 other
isoforms, whose functions are unclear, do not encode the
death domain. In a study of differential expression of LARD
in unstimulated and activated lymphocytes, Screaton and co-
workers found that "...there is no change in overall LARD
expression in different lymphocyte subsets" [55]. Although
total expression levels were unchanged, the pattern of alter-
native splicing changed dramatically (Figure 7). Unstimu-
lated lymphocytes expressed five 'truncated' isoforms, but
very little of the full-length isoform. They found that, "After
lymphocyte activation, there is a complete switch in splicing
that will expose PHA-blasted [activated] cells to the risk of
apoptosis triggered through LARD...The splicing pattern
reverses after PHA blasting when isoforms encoding the trun-
cated molecules are much reduced and LARD-1
predominates."
SWISS-PROT entries with multiple isoforms amenable to analysis generate more PTC+ isoforms Figure 3
SWISS-PROT entries with multiple isoforms amenable to analysis generate more PTC+ isoforms. We categorized SWISS-PROT entries by the number of 
isoforms that are amenable to our analysis, and we then determined how many contained a PTC. Each bar shows the number of PTC+ isoforms generated 
for all SWISS-PROT entries that had the indicated number of isoforms amenable to analysis. Bar components indicate how many entries had a given 
number of PTC+ isoforms. For example, the bar labeled '3' contains data for the 113 SWISS-PROT entries that had 3 isoforms amenable to analysis. 86% 
of these had no PTC+ isoforms, 10% had one PTC+ isoform, and 4% had 2 PTC+ isoforms. The bar components outlined in green were SWISS-PROT 
entries for which all amenable isoforms had a PTC. Entries with multiple isoforms amenable to analysis were more likely to produce at least one PTC+ 
isoform. This study only considered entries with at least two isoforms in the SWISS-PROT database. For many entries only a single isoform is amenable to 
analysis, however.
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Table 1
NMD-candidate SWISS-PROT isoforms
Accession number SWISS-PROT ID Isoform name Gene name(s) cDNA/mRNA
P78314 3BP2_HUMAN SHORT SH3BP2; 3BP2; RES4-23 AB000463
P05023 A1A1_HUMAN SHORT ATP1A1 U16798
Q9NSE7 ABCD_HUMAN 2 ABCC13 AF418600
3 NM_138726
O75078 AD11_HUMAN SHORT ADAM11; MDC NM_021612
Q9P0K1 AD22_HUMAN 2 ADAM22; MDC2 NM_021722
Q9Y6N9 AI75_HUMAN 3 USH1C; AIE75 AF039699
Q92667 AKP1_HUMAN 2 AKAP1; AKAP149 NM_139275
P20594 ANPB_HUMAN SHORT NPR2; ANPRB NM_000907
P18847 ATF3_HUMAN 2 ATF3 NM_004024
Q9H6X2 ATR1_HUMAN MAJOR ANTXR1; ATR; TEM8 NM_032208
Q9NY97 B3G7_HUMAN 2 B3GNT1; B3GALT7 AF288209
Q9HB09 BC12_HUMAN 2 BCL2L12; BPR NM_052842
P13497 BMP1_HUMAN BMP1 6 BMP1 NM_006130
BMP1 5 NM_006131
BMP1 4 NM_006132
Q9HB55 C343_HUMAN 4 CYP3A43 AF280111
P01258 CAL0_HUMAN 2 CALCA; CALC1 M64486
Q9HC96 CANA_HUMAN B CAPN10; KIAA1845 NM_023084
D NM_023086
E NM_023087
F NM_023088
P28907 CD38_HUMAN 2 CD38 D84277
Q08722 CD47_HUMAN OA3 305 CD47 BC037306
O15519 CFLA_HUMAN 9 CFLAR; CLARP; MRIT; 
CASH
AF009617
Q9H2X0 CHRD_HUMAN 3 CHRD AF209930
4 AF283325
O43526 CIQ2_HUMAN 3 KCNQ2 NM_004518
Q9NYG8 CIW4_HUMAN 2 KCNK4; TRAAK NM_016611
P49759 CLK1_HUMAN SHORT CLK1; CLK L29222
P49760 CLK2_HUMAN SHORT CLK2 NM_001291
P49761 CLK3_HUMAN 2 CLK3 NM_001292
Q13286 CLN3_HUMAN 4 CLN3; BTS AF077963
Q99788 CML1_HUMAN MAJOR CMKLR1; DEZ; CHEMR23 U79526
P27815 CN4A_HUMAN 2 PDE4A AF069491
Q9H9E3 COG4_HUMAN 2 COG4 AB088369
Q9Y215 COLQ_HUMAN VII COLQ NM_080543
Q96SM3 CPXM_HUMAN 2 CPXM BC032692
Q9BZJ0 CRN1_HUMAN 4 CRNKL1; CRN AF318304
5 AF318305
Q9BUV8 CT24_HUMAN 4 C20ORF24 BC004446
P57077 CU07_HUMAN B C21ORF7 AF269162
C AF269163
Q9NVD3 CU18_HUMAN B C21ORF18 AF391112
Q92879 CUG1_HUMAN MAJOR CUGBP1; BRUNOL2; 
CUGBP; NAB50
AF248648
O76075 DFFB_HUMAN BETA DFFB; DFF2; DFF40; CAD AB028911
GAMMA AB028912R8.8 Genome Biology 2004,     Volume 5, Issue 2, Article R8       Hillman et al. http://genomebiology.com/2004/5/2/R8
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DELTA AB028913
P25686 DJB2_HUMAN 3 DNAJB2; HSJ1; HSPF3 NM_006736
MAJOR S37374
Q09013 DMK_HUMAN 11 DMPK; MDPK L19268
Q9NYP3 DONS_HUMAN 2 DONSON; C21ORF60 NM_145794
3 NM_145795
Q9NY33 DPP3_HUMAN 2 DPP3 NM_130443
O60941 DTNB_HUMAN 3 DTNB NM_033147
P29320 EPA3_HUMAN MAJOR EPHA3; ETK1; ETK; HEK NM_005233
O75616 ERAL_HUMAN HERA B ERAL1; HERA AF082658
Q92731 ESR2_HUMAN 3 ESR2; NR3A2; ESTRB BC024181
O00507 FAFY_HUMAN SHORT USP9Y; USP10; DFFRY Y13619
P24071 FCAR_HUMAN B DELTA S2 FCAR; CD89 NM_133280
P41439 FOL3_HUMAN SHORT FOLR3 Z32633
O95954 FTCD_HUMAN E FTCD AF289024
P59103 G72_HUMAN MAJOR G72 AY138546
2 NM_172370
Q9UBA6 G8_HUMAN MAJOR C6ORF48; G8 NM_016947
Q9UBS5 GBR1_HUMAN 1E GABBR1 NM_021905
Q9BSJ2 GCP2_HUMAN 2 TUBGCP2; GCP2 BC005011
P56159 GDNR_HUMAN 2 GFRA1; GDNFRA; 
TRNR1; RETL1
NM_145793
O94925 GLSK_HUMAN GAC GLS; KIAA0838 AF158555
Q969S8 HD10_HUMAN 4 HDAC10 AL022328
Q30201 HFE_HUMAN MAJOR HFE; HLAH NM_000410
Q9NRM6 I17S_HUMAN 2 IL17RB; IL17BR; EVI27 NM_172234
Q14790 ICE8_HUMAN 7 CASP8; MCH5 NM_033357
Q92851 ICEA_HUMAN B CASP10; MCH4 NM_001230
C NM_032976
Q92985 IRF7_HUMAN C IRF7 NM_004030
Q01638 IRL1_HUMAN C IL1RL1; ST2; T1; DER4 NM_173459
O14713 ITP1_HUMAN MAJOR ITGB1BP1; ICAP1 NM_004763
2 NM_022334
Q9HCP0 KC11_HUMAN 1S CSNK1G1 NM_022048
P20151 KLK2_HUMAN 3 KLK2 AF188745
Q9H2R5 KLKF_HUMAN 2 KLK15 NM_023006
Q9UJU2 LEF1_HUMAN B LEF1 AF294627
P19256 LFA3_HUMAN SHORT CD58; LFA3 X06296
P53667 LIK1_HUMAN 3 LIMK1; LIMK NM_016735
Q99698 LYST_HUMAN MAJOR CHS1; LYST; CHS NM_000081
P49641 M2A2_HUMAN SHORT MAN2A2; MANA2X NM_006122
O95405 MADI_HUMAN 2 MADHIP; SARA NM_007324
P11137 MAP2_HUMAN MAJOR MAP2 NM_002374
MAP2C NM_031845
P27816 MAP4_HUMAN 2 MAP4 BC015149
P25912 MAX_HUMAN 3 MAX NM_145113
Q15759 MK11_HUMAN BETA 2 MAPK11; PRKM11; SAPK2 NM_002751
O15438 MRP3_HUMAN 3A ABCC3; CMOAT2; MRP3; 
MLP2
NM_020037
3B NM_020038
Table 1 (Continued)
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P21757 MSRE_HUMAN II MSR1 NM_002445
Q9H1B4 NXF5_HUMAN MAJOR NXF5; TAPL1 NM_032946
B NM_033152
C NM_033153
D NM_033154
E NM_033155
Q96QS1 PHMX_HUMAN 5 PHEMX; TSSC6 NM_139023
4 NM_139024
O14829 PPE1_HUMAN 2 PPEF1; PPEF; PPP7C NM_152225
Q9UMR5 PPT2_HUMAN 2 PPT2 NM_138934
Q9NQW5 PRD7_HUMAN MAJOR PRDM7; PFM4 NM_052996
O14818 PSA7_HUMAN 4 PSMA7 NM_152255
P55036 PSD4_HUMAN RPN10E PSMD4; MCB1 NM_153822
P49768 PSN1_HUMAN I 374 PSEN1; PSNL1; AD3; PS1 NM_007319
P23468 PTPD_HUMAN MAJOR PTPRD NM_002839
O75771 R51D_HUMAN 2 RAD51L3; RAD51D NM_133627
Q93062 RBMS_HUMAN MAJOR RBPMS NM_006867
P78563 RED1_HUMAN MAJOR ADARB1; RED1; DRADA2 NM_015833
O15126 SCA1_HUMAN 2 SCAMP1; SCAMP NM_052822
Q13243 SFR5_HUMAN SRP40 2 SFRS5; SRP40; HRS NM_006925
O60902 SHX2_HUMAN MAJOR SHOX2; SHOT; OG12X NM_006884
Q13425 SNB2_HUMAN 2 SNTB2; SNT2B2 NM_130845
Q9Y5W8 SNXD_HUMAN 2 SNX13; KIAA0713 NM_015132
P18583 SON_HUMAN E SON; NREBP; DBP5; 
C21ORF50; KIAA1019
NM_058183
C NM_138926
Q15528 SUR5_HUMAN SURF5A SURF5; SURF-5 NM_006752
O14763 T10B_HUMAN MAJOR TNFRSF10B; DR5; 
TRAILR2; TRICK2; 
KILLER; ZTNFR9
NM_003842
SHORT NM_147187
Q9BZY9 TM31_HUMAN BETA TRIM31 NM_052816
P25445 TNR6_HUMAN 4 TNFRSF6; APT1; FAS; 
FAS1
NM_152873
5 NM_152875
3 NM_152876
2 NM_152877
P00750 TPA_HUMAN SHORT PLAT NM_000931
Q93038 TR12_HUMAN 12 TNFRSF25; TNFRSF12; 
WSL1; WSL; APO3; 
DR3; DDR3
NM_148968
4 NM_148969
3 NM_148971
5 NM_148972
6 NM_148973
7 NM_148974
Q9BYM8 U7I3_HUMAN 4 UBCE7IP3; C20ORF18; 
XAP4
NM_031227
Table 1 (Continued)
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We found that the five truncated LARD mRNA isoforms
shown expressed in unstimulated lymphocytes all have PTCs
(isoforms 2, 3, 4, 5 and 6). (Note that SWISS-PROT uses a dif-
ferent numbering scheme in which isoforms 2-6 are known as
12, 3, 5, 6 and 7, respectively.) Only the full-length apoptosis-
promoting isoform 1, expressed in activated lymphocytes, is
free of a PTC. Although there is presently no evidence of tran-
script degradation, this precise correlation between PTC-con-
taining isoform expression and lymphocyte activation
suggests that the role of alternative splicing in regulating lym-
phocyte apoptosis may be mediated by NMD.
Conclusions
We found that 144 of the human alternative isoforms
described in SWISS-PROT derive from mRNAs that contain
PTCs. These mRNAs are apparent targets for NMD, and we
expect that most are degraded by this system. In many cases,
existing experimental evidence is consistent with this expec-
tation. Because our analysis was restricted to only human
entries and many SWISS-PROT records could not be reliably
analyzed, it is likely that there remain more unidentified
putative NMD targets. We are beginning a collaborative
project with SWISS-PROT to identify and suitably annotate
these entries. The relevance of this effort is highlighted by the
many instances in which existing experimental data can be
explained in the light of NMD action.
Materials and methods
SWISS-PROT isoform extraction and assembly
We analyzed each of the 1,641 SWISS-PROT v.41 human
entries containing a VARSPLIC line in its feature table [39].
Information contained in each VARSPLIC line was used to
assemble protein isoform sequences for 4,556 isoforms from
1,636 unique SWISS-PROT entries. Five entries could not be
analyzed due to ambiguous VARSPLIC annotation.
Identification of corresponding cDNA/mRNA 
sequences
Although SWISS-PROT contains cross-references to cDNA/
mRNA sequences for major protein isoforms, cross-refer-
ences do not exist for many alternative isoforms. To find the
cDNA/mRNA sequence corresponding to each SWISS-PROT
protein isoform, we used BLAST version 2.2.4 [56] to align
each protein isoform sequence to translated cDNA/mRNA
sequences from all GenBank [40] and RefSeq cDNA/mRNA
sequences in these databases as of 22 March 2003 [41]. In
these alignments, we required ≥ 99% identity over the full
length of the SWISS-PROT isoform. In cases of multiple
matches, we selected 100% identical matches over 99% iden-
tical matches and RefSeq matches over GenBank matches.
For SWISS-PROT isoforms matching multiple entries from
the same database at the same percent identity, the match
associated with the longest cDNA/mRNA sequence was cho-
sen. These rules associated 2,871 alternatively spliced human
SWISS-PROT protein isoforms from 1,496 SWISS-PROT
entries with a corresponding cDNA/mRNA sequence from
either RefSeq or Genbank.
Retrieving coding sequences and genomic loci
We used LocusLink [41] to map each cDNA/mRNA sequence
to the correct human genomic contig sequence from the
National Center for Biotechnology Information (NCBI)
human genome build 30 [57]. The coding sequence (CDS)
feature of each GenBank or RefSeq record was used to iden-
tify the location of the termination codon. Of the 2,871 alter-
natively spliced human SWISS-PROT protein isoforms we
associated with corresponding cDNA/mRNA sequences,
2,742 had GenBank or RefSeq records that were not
2 NM_031228
P58418 USH3_HUMAN B USH3A NM_174880
Q9NP71 WS14_HUMAN 5 WBSCR14; MIO NM_032994
Q02040 XE7_HUMAN SHORT (XE7X; XE7; DXYS155E); 
(XE7Y; XE7; DXYS155E)
NM_005088
Q9Y493 ZAN_HUMAN 1 ZAN NM_173055
2 NM_173056
4 NM_173057
5 NM_173058
The 144 alternatively spliced human protein isoforms from SWISS-PROT V.41 whose mRNA transcripts contain premature-termination codons are 
listed. The SWISS-PROT accession number, SWISS-PROT identifier, gene name(s), and cDNA/mRNA sequence for each isoform are given. Isoforms 
discussed in the text are in bold. Isoforms labeled "MAJOR" are those whose sequence is displayed in SWISS-PROT for that entry. These isoforms 
are not necessarily the most abundant.
Table 1 (Continued)
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polycistronic, allowing us to unambiguously determine the
termination codon location for these records. These 2,742
alternative isoforms represented 1,463 unique SWISS-PROT
entries.
Assessing NMD candidacy
The SPIDEY mRNA-to-genomic DNA alignment program
[42] was used to determine the location of introns in each
cDNA/mRNA alternative isoform sequence. SPIDEY takes as
input a cDNA/mRNA sequence and the corresponding
genomic sequence, and it generates an alignment that estab-
lishes the gene structure. Of the 2,742 alternatively spliced
human SWISS-PROT protein isoforms for which both a
cDNA/mRNA sequence and stop codon location could be
identified, 2,483 resulted in high-confidence SPIDEY align-
ments, leading us to discard 259 from our analysis. These
2,483 isoform sequences represented 1,363 unique SWISS-
PROT entries. We compared the intron positions to the posi-
tion of the termination codon for each remaining cDNA/
mRNA alternative isoform sequence. If the termination
codon was found to be more than 50 nucleotides upstream of
the final intron, we deemed the transcript to be PTC+ and a
Published expression levels of calpain-10 isoforms are consistent with NMD prediction Figure 4
Published expression levels of calpain-10 isoforms are consistent with NMD prediction. (a) A report from Horikawa and co-workers [43] found eight 
alternative isoforms of calpain-10, of which four are expressed in low abundance. Our analysis found this exact set of four low-abundance isoforms to 
contain PTCs. (b) Gene structures of alternative mRNA isoforms of calpain-10 show the patterns of alternative splicing and indicate locations of PTCs. 
Also shown is the position of UCSNP-43, an intronic polymorphism that has been statistically linked to type II diabetes susceptibility in a variety of 
populations.
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(a) (b)R8.12 Genome Biology 2004,     Volume 5, Issue 2, Article R8       Hillman et al. http://genomebiology.com/2004/5/2/R8
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Splicing to generate a premature termination codon is evolutionarily conserved in CLKs Figure 5
Splicing to generate a premature termination codon is evolutionarily conserved in CLKs. The CDC-like kinases (CLKs) are splicing regulators that affect 
splicing decisions through the phosphorylation of SR proteins. (a) Our screen of SWISS-PROT revealed that human CLK1, CLK2 and CLK3 paralogs all 
generate PTC+ alternative isoforms. The splicing pattern that generates these isoforms, skipping exon 4, is conserved in each. This splicing pattern causes 
a frameshift and a PTC. The percent identities from global alignments between corresponding exons and introns are shown in purple. (b) CLKs were 
identified in mouse through existing annotation and in the predicted genes of the sea squirt C. intestinalis using an HMM constructed with annotated CLKs 
from a variety of organisms. An EST analysis revealed that the alternative splicing pattern that generates PTC+ alternative isoforms was conserved in all 
three sets of orthologs in human and mouse. The same splicing pattern was also found in the only C. intestinalis homolog. A relatively high degree of 
sequence similarity was found to be present in the introns flanking the alternative exon.
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candidate target for NMD according to the model of mamma-
lian PTC recognition [14]. One hundred and seventy-seven
alternatively spliced human isoforms from 130 SWISS-PROT
entries were identified as possible PTC+ splice variants using
these criteria. These predictions required further screening,
however, to confirm the veracity of the SPIDEY alignments on
which they were based.
We manually reviewed all 177 putatively PTC+ alignments and
discarded 33 because of demonstrable errors in the SPIDEY
alignments. These errors included a variety of malformed
intron predictions and poly(A) tails mistakenly annotated as
3' exons. Isoforms that remained following the application of
these manual filters were deemed high-confidence PTC+
mRNAs. This was the case for 5.8% of the isoforms (144 of
2,483) from 7.9% of the unique SWISS-PROT entries studied
(107 of 1,363). The SPIDEY alignment for each of these is
included in Additional data file 1; the sequence identifiers for
each step are included in Additional data file 2.
CLK analysis
Human CLK1, CLK2 and CLK3 (SWISS-PROT IDs P49759,
P49760, and P49761) were among those SWISS-PROT
entries we selected for further examination. They were
mapped to RefSeq and GenBank entries, as shown in Figure
2. LocusLink was used to associate each CLK gene sequence
to its corresponding genomic contig. For each gene, SPIDEY
version 1.35 was run twice, using the vertebrate splice-site
setting, to align it with its contig sequence and determine its
gene structure. This first SPIDEY alignment was used to
define the extent of each gene's locus: the region containing
all the coding sequence, introns, and 1,000 nucleotides of
flanking sequence on each side. The second SPIDEY align-
ment was made using just this locus. Custom scripts
(available from the authors on request), GFF2PS [58], and
manual editing were used to generate the graphical represen-
tations of the gene structures shown in Figure 4. Intron and
exon sequences were then extracted using the SPIDEY results
to delineate exon and intron boundaries. Corresponding
exons and introns were globally aligned using ALIGN version
2.0u [59] with default parameters.
Mouse CLKs were identified using RefSeq annotation
(NM_009905 - which skipped exon 4 and had a PTC,
NM_007712, and NM_007713). Genomic loci sequences
were generated and gene structures determined for each
mouse CLK gene using SPIDEY, as above. The loci sequences
were then used to search the mouse ESTs from dbEST (1 May
2003) [60] using WU-BLAST 2.0MP (23 May 2003) [61] with
default parameters. Hits with E-values of 10-30 or better were
aligned to the locus sequence using SPIDEY. These align-
ments were examined for evidence of PTC-inducing alterna-
tive splicing. The GI numbers for ESTs that exhibited the
alternative splicing pattern shown in Figure 3 for each of the
mouse CLKs are: CLK1 (full-length): 25118521, 21852543,
12560958, and others; CLK2 (exon 4 skipping): 22822098;
CLK3 (exon 4 skipping): 26079129.
The C. intestinalis CLK homolog was identified from the data-
base of predicted peptides [62,63] by searching
(HMMSEARCH V2.2G) [64] with a HMMER model of known
CLKs. This model was generated using HMMBUILD (default
parameters) and calibrated using HMMCALIBRATE from a
CLUSTAL W V1.83 [65] alignment of the following CLK
sequences: NP_004062, NP_003984, NP_003983,
NP_031738, BAB33079, NP_031740, NP_065717,
AAH43963, NP_599167, NP_031739, NP_477275,
EAA12103, NP_741928, BAB67874, and NP_850695. The
most significant hit (E-value: 4.4e-243) from C. intestinalis
was ci0100143784. Visual inspection of other, less significant
hits revealed that they align with only the kinase domain of
the CLK model and none contains the LAMMER motif char-
acteristic of CLKs. A maximum-likelihood tree was generated
using PROTML V2.3B3 [66] using ci0100143784 and the
three full-length human CLKs. This tree revealed that the C.
intestinalis CLK is orthologous to human CLK2. The corre-
Cycloheximide increases abundance of CLK1 PTC+ isoform Figure 6
Cycloheximide increases abundance of CLK1 PTC+ isoform. (a) Gene 
structures of CLK1 full-length and PTC+ isoforms as determined by our 
analysis. (b) Menegay et al. [48] performed the RT-PCR analysis of CLK1 
isoforms; Figure 8 of that analysis [48] is reproduced here with permission 
(© Company of Biologists Ltd.). The 560 bp fragment corresponds to the 
full-length CLK1 isoform; the 453 bp fragment corresponds to the PTC+ 
CLK1 isoform. The analysis shows that cycloheximide, but not UV 
irradiation or high salt (data not shown), increased the relative abundance 
of the CLK1 isoform containing a premature termination codon. As 
cycloheximide is a potent inhibiter of NMD (see, for example, [28,51-53]), 
this result suggests that the CLK1 PTC+ isoform is degraded by NMD. 
Menegay et al. [48] describe their figure as follows: "Shift in PCR products 
of splice forms with cycloheximide. Control or PC12 cells treated with 10 
µg/ml cycloheximide for 60 minutes were harvested, RNA was extracted, 
and RT-PCR was performed. [...] PCR products of the 560 bp full-length 
form or the 453 kinase-less form of CLK1 message shown. [...] PCR of 
GAPDH controls from each sample to control for RNA loading."
STOP Full-length isoform
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Reproduced with
permission from [48]
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s p o n d i n g  c D N A  t r a n s c r i p t  sequence, ci0100143784, was
retrieved from the database of predicted transcripts [67].
As above, the locus for this gene was extracted from the
genomic contig sequence, Scaffold18, and used to search the
database of C. intestinalis ESTs. The following ESTs showed
the full-length pattern with no PTC: 24144377, 24820603,
24627564, 24627468, 24866887, and 2482449. The follow-
ing ESTs showed the alternatively spliced pattern that gener-
ates a PTC: 24888181, 24606693, 24823992, and 24893089.
The C. intestinalis CLK gene was found to have only 11 exons,
whereas human and mouse CLK2 h a v e  1 3 .  T o  d e t e r m i n e
which exons were homologous, we generated a CLUSTALW
multiple-sequence alignment of the known CLK protein
sequences listed above and C. intestinalis CLK and used this
alignment to identify corresponding regions of DNA
sequence. This unambiguously indicated the exon-to-exon
alignment shown in Figure 4.
Additional data files
A table showing the raw SPIDEY output of the 144 NMD-can-
didate isoform genes (Additional data file 1) and a file con-
taining the identifiers of sequences at each major step of the
analysis pipeline (Additional data file 2) are available with the
online version of this article.
Additional data file 1 A table showing the raw SPIDEY output of the 144 NMD-candidate  isoform genes A table showing the raw SPIDEY output of the 144 NMD-candidate  isoform genes Click here for additional data file Additional data file 2 A file containing the identifiers of sequences at each major step of  the analysis pipeline A file containing the identifiers of sequences at each major step of  the analysis pipeline Click here for additional data file
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